The Motley Fool

Turn £10k Into £30k With AstraZeneca plc

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

AstraZenecaIf you’d held AstraZeneca (LSE: AZN) (NYSE: AZN.US) shares over the past 12 months, you’d have done pretty nicely with a 40% rise to 4,544p.

A lot of that is down to the Pfizer bid, mind, but the turnaround plan put in place by new boss Pascal Soriot was already boosting the shares. And over three years you’d be sitting on a gain of more than 60%.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

But Fools are in it for the long term, so what would an investment in AstraZeneca a full 10 years ago be worth now?

Double your money

In September 2004, AstraZeneca shares were changing hands for around 2,265p, so if you’d invested £10,000 at the time you would have picked up 442 shares. Wind forward to today, and with AstraZeneca shares priced at 4,544p you’d have enjoyed a 101% capital gain — you’d have more than doubled your £10,000 in 10 years to £20,062.

Bear in mind that the period covered two traumatic events for AstraZeneca. One was the recession that hit the entire FTSE, but we also had the so-called patent cliff that saw the end of protection of some key drugs. Between late 2006 and early 2008, AstraZeneca shares lost a massive 49%, and investors could be forgiven for not being too impressed by the stock market at the time.

But even if you’d bought in at the very peak of 2006 and suffered the crunch, your shares would still be worth 30% more today! As failures go, I’ve seen worse.

Don’t forget the dividends

If that 10-year doubling impressed you, don’t forget there’s more to come in the shape of dividends. Early in the decade, AstraZeneca was handing out yields of between 2% and 3%, which was a little below the FTSE 100 average. But the dividend was on the rise, and by 2009 it was yielding 5% — and it got as high as 6.1% in 2011.

Altogether, the annual cash handout would have netted you an additional £5,617, giving you a total of £25,679 for an overall return of 157%.

But we don’t want to give you that!

Buy more shares!

No, if you hadn’t needed to spend your dividends, you’d have built an even bigger pot had you reinvested the cash in more AstraZeneca shares every year.

Just those few extra few shares every year would have added another £4,471 to your investment! That’s an extra 45% return on your original £10,000.

Your total gain with all dividends reinvested over 10 years? A pretty cool £30,150! And you’d be starting the next decade with 639 shares instead of your original 442.

One Killer Stock For The Cybersecurity Surge

Cybersecurity is surging, with experts predicting that the cybersecurity market will reach US$366 billion by 2028more than double what it is today!

And with that kind of growth, this North American company stands to be the biggest winner.

Because their patented “self-repairing” technology is changing the cybersecurity landscape as we know it…

We think it has the potential to become the next famous tech success story.

In fact, we think it could become as big… or even BIGGER than Shopify.

Click here to see how you can uncover the name of this North American stock that’s taking over Silicon Valley, one device at a time…

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.